AI & Multi-omics for
Translational Research
Innovations driving drug discovery breakthroughs and shaping future-ready strategies
Date: December 03, 2025
Duration: 60 minutes
How AI, Genomics & Proteomics Are Redefining Biomarker Discovery
Unlock on-demand access to insights from leaders shaping the future of translational research. As precision medicine accelerates, the most transformative breakthroughs are emerging where AI-powered analytics, multi-omic integration, biomarker strategy, and biospecimen excellence converge.
In this expert panel featuring innovators from Precision for Medicine, SOPHiA GENETICS, and Olink (Part of Thermo Fisher Scientific), you’ll gain practical insights into how top biopharma organizations are building scalable, predictive, and scientifically robust multi-omic strategies for the next era of clinical development.
What You'll Gain
- Insights From Industry Leaders Driving AI & Multi-omics Innovation: Learn how cutting-edge AI, genomic, and proteomic platforms are being applied across translational science to accelerate biomarker discovery, optimize assay selection, and generate actionable clinical insights.
- Insights on Building a Connected Multi-omic Strategy From Specimen to Decision: Understand why successful translational programs require alignment of biospecimen planning, assay development, and analytic pipelines and how multi-omics reveals biological variability missed by single-modality approaches.
- Practical Framework for Implementation: Walk away with a clear execution model on how to integrate AI with multi-omic workflows, design biospecimen strategies and operationalize multi-omic platforms to support predictive biomarkers and clinical decision-making
Speakers
-
Deborah Phippard, PhD
Chief Scientific Officer, Precision for Medicine. Pharma industry veteran and expert at biomarker-driven clinical trial design and execution. Leader of biomarker and drug development programs for pharmaceutical and diagnostics companies, as well as the National Institutes of Health. Spearheaded the discovery of pharmacodynamic biomarkers and novel targets for inflammatory disease therapy.
(SizeLimitingPyList: [linkedin]) -
Dr. Philippe Menu, MD, PhD, MBA,
EVP, Chief Medical Officer & Chief Product Officer at SOPHiA GENETICS. Dr. Philippe Menu joined SOPHiA GENETICS in 2020 as Chief Medical Officer, bringing a unique blend of medical expertise across clinical medicine, fundamental research in molecular biology, and business management consulting. Before joining SOPHiA GENETICS, he spent 8 years at McKinsey & Company serving dozens of clients in the BioPharma sector, advising global pharmaceutical companies, mid-size players, and biotechs alike across the pharma value chain with a major focus on innovative therapies and diagnostics in oncology and rare diseases. Philippe obtained his MD and PhD from the University of Lausanne and his MBA in life sciences from the Open University Business School.
(SizeLimitingPyList: [linkedin]) -
Heng (Tony) Qian
Head of Data Science (North America), Olink, part of Thermo Fisher Scientific. Tony Qian leads the Americas Data Science team at Olink, driving innovation in proteomics research through continuous enhancements to the Olink data science ecosystem. His work focuses on empowering researchers with advanced analytical tools and scalable solutions. Previously, Tony specialized in developing infectious disease and genomics products within the in vitro diagnostics (IVD) industry, combining deep technical expertise with a strong understanding of clinical applications.
(SizeLimitingPyList: [linkedin]) -
Rob Fannon
Head of Biospecimen Solutions, Precision for Medicine. Respected veteran of the biospecimen and biomarker laboratory services industry. Honed his expertise through leadership roles in organizations including Roche, Cancer Genetics, and BioServe. Holds a Master of Public Health and a Master of Business Administration from Johns Hopkins University.
(SizeLimitingPyList: [linkedin])